| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2022 | -87.91% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 20.92% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -87.91% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -69.77% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -63.72% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -85.49% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -39.54% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 81.38% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | -27.45% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 226.48% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 33.01% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
| 09/08/2017 | -27.45% | Morgan Stanley | → $6 | Initiates Coverage On | → Equal-Weight |
| 07/21/2017 | 20.92% | Deutsche Bank | → $10 | Initiates Coverage On | → Buy |
TherapeuticsMD Questions & Answers
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on July 13, 2022. The analyst firm set a price target for $1.00 expecting TXMD to fall to within 12 months (a possible -87.91% downside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD reiterated their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on July 13, 2022 so you should expect the next rating to be made available sometime around July 13, 2023.
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $1.00. The current price TherapeuticsMD (TXMD) is trading at is $8.27, which is out of the analyst's predicted range.